Open Payments

Langley Porter Psychiatric Hospital

Type
Teaching hospital
Where
San Francisco, CA
Medicare CCN
054144
Received
$69,769,161 in 3,604 records, 2025 ($7,257,255 general, $62,511,906 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment498$7,257,255
2025Research payment3,106$62,511,906

By company

CompanyRecordsAmountYears
Genentech, Inc.182$12,056,6022025
Merck Sharp & Dohme LLC73$8,885,8452025
Abbott Laboratories66$3,983,6052025
E.R. Squibb & Sons, L.L.C.51$3,517,9132025
AstraZeneca Pharmaceuticals LP27$3,162,7532025
F. Hoffmann-La Roche AG116$3,061,1372025
PFIZER INC.213$2,557,3902025
Janssen Research & Development, LLC216$2,284,0792025
Amgen Inc.21$2,144,3062025
ABBVIE INC.195$1,620,9092025
Gilead Sciences, Inc.30$1,512,5232025
UCB, Inc.3$1,463,2622025
Regeneron Pharmaceuticals, Inc.242$1,320,2932025
GE HEALTHCARE33$1,313,8882025
Celgene Corporation18$1,310,9232025
Intuitive Surgical, Inc.138$881,9642025
Ipsen Bioscience Inc.2$814,6492025
Janssen Biotech, Inc.5$774,8512025
Ultragenyx Pharmaceutical Inc.21$689,3692025
Boston Scientific Corporation32$604,4492025
Novo Nordisk AS5$577,0372025
Hoffmann-La Roche Limited32$569,1162025
Edwards Lifesciences Corporation58$550,4002025
Eli Lilly and Company15$543,7282025
BioMarin Pharmaceutical Inc.48$536,9212025
Stryker Corporation43$526,7812025
Alexion Pharmaceuticals, Inc.13$492,6152025
AstraZeneca UK Limited8$452,7122025
VERTEX PHARMACEUTICALS INCORPORATED13$451,0222025
SEAGEN INC.7$396,1462025
Takeda Pharmaceuticals U.S.A., Inc.57$392,1332025
United Therapeutics Corporation50$361,0342025
Paragonix Technologies, Inc.6$328,5592025
Medtronic, Inc.24$315,5162025
KAMADA LTD.3$307,2982025
Alkermes, Inc.179$304,7492025
Boehringer Ingelheim Pharmaceuticals, Inc.11$288,2842025
Servier BioInnovation148$286,6582025
Astellas US Technologies2$280,9002025
Davol Inc.6$279,6352025
SANOFI US SERVICES INC.25$266,4022025
Eisai Inc.56$254,5112025
Agios Pharmaceuticals, Inc.24$248,1112025
Incyte Corporation15$243,1722025
Roche TCRC, Inc.94$232,8752025
Madrigal Pharmaceuticals44$232,1022025
Ascendis Pharma Endocrinology Inc114$222,5452025
GENZYME CORPORATION11$219,4682025
ARGENX US, INC.33$206,4082025
Biogen, Inc.4$206,3812025

By nature of payment

NatureRecordsAmount
Research payment3,106$62,511,906
Grant77$3,432,134
Compensation for services other than consulting, including serving as faculty or as a speaker at a v177$1,464,687
Space rental or facility fees (teaching hospital only)180$980,228
Consulting Fee14$824,729
Education14$288,124
Royalty or License19$120,773
Long term medical supply or device loan8$92,789
Gift4$33,087
Charitable Contribution5$20,700

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31Merck Sharp & Dohme LLC$1,974,719Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 2 Study of Pembrolizumab Plus 177Lu-PSMA-617 in Patients with Metastatic Castration Resistant Prostate Cancer2025
2025-12-31Merck Sharp & Dohme LLC$1,925,132Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYSTUDY NAME#A phase II study of stereotactic radiosurgery in conjunction with PD-1 inhibitor Pembrolizumab for the treatm2025
2025-12-31Merck Sharp & Dohme LLC$296,088Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYSTUDY NAME#Phase Ib,II Study of Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy as a Bladder-Sparing Tri2025
2025-12-31Merck Sharp & Dohme LLC$125,386Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# Substudy 03C in P2025
2025-12-31Merck Sharp & Dohme LLC$64,367Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N2025
2025-12-31Paragonix Technologies, Inc.$58,773Research paymentCash or cash equivalentLungGuard Device, PulmonologyObservational Study of Lung Preservation2025
2025-12-31PFIZER INC.$54,686Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2025
2025-12-31Merck Sharp & Dohme LLC$54,619Research paymentIn-kind items and services Biological, ONCOLOGYA Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan sac-TMT, MK-2870 as a M2025
2025-12-31Merck Sharp & Dohme LLC$48,857Research paymentIn-kind items and servicesWINREVAIR Biological, CARDIOVASCULARA Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sotatercept M2025
2025-12-31Merck Sharp & Dohme LLC$37,894Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2025
2025-12-31PFIZER INC.$32,798Research paymentCash or cash equivalentA PHASE 1 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARM2025
2025-12-31Merck Sharp & Dohme LLC$30,157Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV With an2025
2025-12-31Merck Sharp & Dohme LLC$29,889Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# Substudy 03A in F2025
2025-12-31Merck Sharp & Dohme LLC$29,820Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# substudy 03B in S2025
2025-12-31Merck Sharp & Dohme LLC$27,711Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# Substudy 03C in P2025
2025-12-31Merck Sharp & Dohme LLC$21,745Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in P2025
2025-12-31Merck Sharp & Dohme LLC$19,869Research paymentIn-kind items and servicesWINREVAIR Biological, CARDIOVASCULARAn Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri2025
2025-12-31Merck Sharp & Dohme LLC$18,435Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently2025
2025-12-31Merck Sharp & Dohme LLC$15,947Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin2025
2025-12-31Merck Sharp & Dohme LLC$11,761Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT2025
2025-12-31ABBVIE INC.$8,251Research paymentCash or cash equivalentRINVOQ Biological, IMMUNOLOGYStudy to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric 2025
2025-12-31ABBVIE INC.$7,957Research paymentCash or cash equivalentSKYRIZI Biological, IMMUNOLOGYA Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease2025
2025-12-31Merck Sharp & Dohme LLC$5,867Research paymentIn-kind items and servicesStudy to Evaluate Sampling Methods for Detection of Human Papillomavirus HPV in the Anogenital Region of Males2025
2025-12-31Merck Sharp & Dohme LLC$5,545Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad2025
2025-12-31PFIZER INC.$4,198Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTA2025
2025-12-31Merck Sharp & Dohme LLC$3,385Research paymentIn-kind items and servicesWINREVAIR Biological, CARDIOVASCULARAn Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri2025
2025-12-31PFIZER INC.$3,089Research paymentCash or cash equivalentAN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS2025
2025-12-31Sterilmed, Inc.$2,604Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-12-31Merck Sharp & Dohme LLC$2,365Research paymentIn-kind items and servicesPADCEV Biological, ONCOLOGYA Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV With an2025
2025-12-31Merck Sharp & Dohme LLC$2,036Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase II study of lenvatinib plus pembrolizumab in well differentiated G3 neuroendocrine tumors2025
2025-12-31iRhythm Technologies, Inc.$1,420Research paymentIn-kind items and servicesZIO XT Patch Device, Cardiology/Vascular DiseasesSTUDY-Full Proof2025
2025-12-31Merck Sharp & Dohme LLC$1,216Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAn Open Label, First in Human FIH, Phase 1 Trial of LVGN6051 as Single Agent and in Combination with Keytruda pembrolizu2025
2025-12-31Merck Sharp & Dohme LLC$1,024Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus 2025
2025-12-31ABBVIE INC.$600Research paymentIn-kind items and servicesA Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Meta2025
2025-12-31Merck Sharp & Dohme LLC$350Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for 2025
2025-12-31ABBVIE INC.$295Research paymentIn-kind items and servicesRINVOQ Biological, IMMUNOLOGYA Phase 3 Multicenter Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Upadacitinib with Open-Label Induction2025
2025-12-31Tanabe Pharma America, Inc.$70Research paymentIn-kind items and servicesA Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon 2025
2025-12-31Alkermes, Inc.$42Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-12-31ABBVIE INC.$24Research paymentIn-kind items and servicesEPKINLY Drug, ONCOLOGYA Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffus2025
2025-12-30Mirati Therapeutics, Inc.$19,383Research paymentCash or cash equivalentKRAZATI Drug, OncologyPhase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutat2025
2025-12-30Daiichi Sankyo Inc.$3,465Research paymentCash or cash equivalentDS3201-A-U2022025
2025-12-30Celgene Corporation$2,025Royalty or LicenseCash or cash equivalent2025
2025-12-30Celgene Corporation$2,025Royalty or LicenseCash or cash equivalent2025
2025-12-29Genentech, Inc.$42,886Research paymentCash or cash equivalentOcrevus Biological, ImmunologyIdentifying ocrelizumab-resistant lymphocytes in lymphoid tissue in multiple sclerosis2025
2025-12-29Genentech, Inc.$36,505Consulting FeeCash or cash equivalent2025
2025-12-29Janssen Research & Development, LLC$9,351Research paymentCash or cash equivalentDARZALEX Drug, OncologyA Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D2025
2025-12-29Janssen Research & Development, LLC$7,034Research paymentCash or cash equivalentPhase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or2025
2025-12-29Genentech, Inc.$2,969Research paymentCash or cash equivalentOcrevus Biological, ImmunologyIdentifying ocrelizumab-resistant lymphocytes in lymphoid tissue in multiple sclerosis2025
2025-12-26Regeneron Pharmaceuticals, Inc.$15,538Research paymentCash or cash equivalentA DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT2025
2025-12-26Regeneron Pharmaceuticals, Inc.$15,538Research paymentCash or cash equivalentA DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT2025
2025-12-26Regeneron Pharmaceuticals, Inc.$13,397Research paymentCash or cash equivalentA DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT2025
2025-12-26Regeneron Pharmaceuticals, Inc.$13,397Research paymentCash or cash equivalentA DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT2025
2025-12-26Regeneron Pharmaceuticals, Inc.$13,397Research paymentCash or cash equivalentA DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT2025
2025-12-26Regeneron Pharmaceuticals, Inc.$4,033Research paymentCash or cash equivalentA DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT2025
2025-12-26KARL STORZ Endoscopy-America$4,000GrantCash or cash equivalent2025
2025-12-26Regeneron Pharmaceuticals, Inc.$3,896Research paymentCash or cash equivalentA DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT2025
2025-12-26Regeneron Pharmaceuticals, Inc.$3,896Research paymentCash or cash equivalentA DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT2025
2025-12-26Regeneron Pharmaceuticals, Inc.$3,896Research paymentCash or cash equivalentA DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT2025
2025-12-26Regeneron Pharmaceuticals, Inc.$2,599Research paymentCash or cash equivalentA DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT2025
2025-12-26Regeneron Pharmaceuticals, Inc.$2,203Research paymentCash or cash equivalentA DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT2025
2025-12-26Regeneron Pharmaceuticals, Inc.$2,138Research paymentCash or cash equivalentA DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA X CD3 BISPECIFIC ANTIBODIES) FOR DESENSITIZAT2025
2025-12-25Janssen Research & Development, LLC$10,275Research paymentCash or cash equivalentTREMFYA Drug, ImmunologyImmunogenetic Profiling Of Guselkumab For The Treatment Of Plaque And Guttate Psoriasis2025
2025-12-24Incyte Corporation$20,610Research paymentCash or cash equivalentA Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and 2025
2025-12-24United Therapeutics Corporation$15,000EducationCash or cash equivalent2025
2025-12-24Genmab U.S., Inc.$14,827Research paymentCash or cash equivalentEpkinly Drug, OncologyA Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma.2025
2025-12-24United Therapeutics Corporation$3,790Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-12-24United Therapeutics Corporation$3,790Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-12-24United Therapeutics Corporation$3,371Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-12-24SERVIER PHARMACEUTICALS LLC$1,056Research paymentCash or cash equivalentA PHASE I, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION, SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC, AND CLINICA2025
2025-12-24Roche TCRC, Inc.$350Research paymentCash or cash equivalentPhase II study in early stage Parkinson s Disease Patients2025
2025-12-24Roche TCRC, Inc.$350Research paymentCash or cash equivalentPhase II study in early stage Parkinson s Disease Patients2025
2025-12-24Roche TCRC, Inc.$256Research paymentCash or cash equivalentPhase II study in early stage Parkinson s Disease Patients2025
2025-12-23Genentech, Inc.$106,666Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-12-23Gilead Sciences, Inc.$98,000Research paymentCash or cash equivalentDescovy Drug, HIVThe impact of CASB159 on the trend of PrEP uptake and HIV infection rate on a state and local level2025
2025-12-23Genentech, Inc.$70,903Research paymentCash or cash equivalentA PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS2025
2025-12-23Genentech, Inc.$22,786Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-12-23Genentech, Inc.$22,786Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-12-23Alkermes, Inc.$10,552Research paymentCash or cash equivalentA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-12-23Alkermes, Inc.$10,552Research paymentCash or cash equivalentA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-12-23Alkermes, Inc.$8,213Research paymentCash or cash equivalentA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-12-23Alkermes, Inc.$8,213Research paymentCash or cash equivalentA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-12-23Alkermes, Inc.$8,007Research paymentCash or cash equivalentA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-12-23Gilead Sciences, Inc.$8,000Research paymentCash or cash equivalentDescovy Drug, HIVThe impact of CASB159 on the trend of PrEP uptake and HIV infection rate on a state and local level2025
2025-12-23Alkermes, Inc.$3,284Research paymentCash or cash equivalentA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-12-23Alkermes, Inc.$3,284Research paymentCash or cash equivalentA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-12-23Alkermes, Inc.$3,059Research paymentCash or cash equivalentA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-12-22Novo Nordisk AS$553,754Research paymentCash or cash equivalent2025
2025-12-22Genentech, Inc.$45,774Research paymentCash or cash equivalentActemra Biological, ImmunologyPhase 1 EIH CD19 4 1BBL2025
2025-12-22BioMarin Pharmaceutical Inc.$14,055Research paymentCash or cash equivalentVOXZOGO 1.2mg Drug, AchondroplasiaA Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondrop2025
2025-12-22Janssen Research & Development, LLC$13,818Research paymentCash or cash equivalentTREMFYA Drug, ImmunologyImmune Spatial Features of Guselkumab Cutaneous Response2025
2025-12-22BioMarin Pharmaceutical Inc.$10,215Research paymentCash or cash equivalentVOXZOGO 1.2mg Drug, AchondroplasiaA Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondrop2025
2025-12-22HARMONY BIOSCIENCES LLC$3,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentWAKIX Drug, NARCOLEPSY2025
2025-12-22BioMarin Pharmaceutical Inc.$2,819Research paymentCash or cash equivalentVOXZOGO 1.2mg Drug, AchondroplasiaBMN 111-9032025
2025-12-22Janssen Research & Development, LLC$2,308Research paymentCash or cash equivalentA Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Co2025
2025-12-22BioMarin Pharmaceutical Inc.$2,162Research paymentCash or cash equivalentVOXZOGO 1.2mg Drug, AchondroplasiaBMN 111-9022025
2025-12-22Genmab A/S$416Research paymentCash or cash equivalentEpkinly Drug, OncologyA Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) 2025
2025-12-19Genentech, Inc.$149,390Research paymentCash or cash equivalentA Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease2025
2025-12-19PFIZER INC.$38,206Research paymentCash or cash equivalentA PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTI2025
2025-12-19ARGENX US, INC.$33,188Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyA Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH2025
2025-12-19F. Hoffmann-La Roche AG$14,782Research paymentCash or cash equivalentOcrevus Biological, ImmunologyRoll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE2025
2025-12-19F. Hoffmann-La Roche AG$14,160Research paymentCash or cash equivalentOcrevus Biological, ImmunologyRoll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE2025
2025-12-19F. Hoffmann-La Roche AG$14,160Research paymentCash or cash equivalentOcrevus Biological, ImmunologyRoll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE2025
2025-12-19F. Hoffmann-La Roche AG$13,458Research paymentCash or cash equivalentOcrevus Biological, ImmunologyRoll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE2025
2025-12-19Intuitive Surgical, Inc.$9,144Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and servicesDAVINCI XI Device, SURGERY2025
2025-12-19F. Hoffmann-La Roche AG$7,192Research paymentCash or cash equivalentOcrevus Biological, ImmunologyRoll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE2025
2025-12-19F. Hoffmann-La Roche AG$7,192Research paymentCash or cash equivalentOcrevus Biological, ImmunologyRoll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE2025
2025-12-19F. Hoffmann-La Roche AG$6,490Research paymentCash or cash equivalentOcrevus Biological, ImmunologyRoll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE2025
2025-12-19F. Hoffmann-La Roche AG$6,490Research paymentCash or cash equivalentOcrevus Biological, ImmunologyRoll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE2025
2025-12-19Edwards Lifesciences Corporation$6,408Research paymentCash or cash equivalentTRISCEND II Pivotal (2020-05)2025
2025-12-19Madrigal Pharmaceuticals$5,742Research paymentCash or cash equivalentREZDIFFRA Drug, LIVER DISEASEA 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET2025
2025-12-19Intuitive Surgical, Inc.$4,356Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and servicesDAVINCI XI Device, SURGERY2025
2025-12-19ARGENX US, INC.$3,960Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyA Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH2025
2025-12-19Hoffmann-La Roche Limited$3,000Research paymentCash or cash equivalentPH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD2025
2025-12-19PFIZER INC.$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVYNDAQEL Drug, CARDIOVASCULAR2025
2025-12-19Madrigal Pharmaceuticals$2,280Research paymentCash or cash equivalentREZDIFFRA Drug, LIVER DISEASEA 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET2025
2025-12-19F. Hoffmann-La Roche AG$2,038Research paymentCash or cash equivalentOcrevus Biological, ImmunologyRoll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE2025
2025-12-19AstraZeneca UK Limited$1,120Research paymentCash or cash equivalentA Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Rece2025
2025-12-19F. Hoffmann-La Roche AG$732Research paymentCash or cash equivalentOcrevus Biological, ImmunologyRoll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE2025
2025-12-19F. Hoffmann-La Roche AG$732Research paymentCash or cash equivalentOcrevus Biological, ImmunologyRoll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE2025
2025-12-19F. Hoffmann-La Roche AG$732Research paymentCash or cash equivalentOcrevus Biological, ImmunologyRoll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE2025
2025-12-19F. Hoffmann-La Roche AG$732Research paymentCash or cash equivalentOcrevus Biological, ImmunologyRoll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE2025
2025-12-19F. Hoffmann-La Roche AG$732Research paymentCash or cash equivalentOcrevus Biological, ImmunologyRoll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE2025
2025-12-19F. Hoffmann-La Roche AG$732Research paymentCash or cash equivalentOcrevus Biological, ImmunologyRoll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE2025
2025-12-19F. Hoffmann-La Roche AG$732Research paymentCash or cash equivalentOcrevus Biological, ImmunologyRoll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE2025
2025-12-19F. Hoffmann-La Roche AG$732Research paymentCash or cash equivalentOcrevus Biological, ImmunologyRoll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE2025
2025-12-19F. Hoffmann-La Roche AG$732Research paymentCash or cash equivalentOcrevus Biological, ImmunologyRoll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE2025
2025-12-19F. Hoffmann-La Roche AG$730Research paymentCash or cash equivalentOcrevus Biological, ImmunologyRoll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE2025
2025-12-18Tanabe Pharma America, Inc.$55,600Research paymentCash or cash equivalentReducing diagnostic delays in erythropoietic protoporphyria using a machine learning approach2025
2025-12-18Boston Scientific Corporation$21,973Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentGeneral - Tachy Device, General - Tachy_CRM2025
2025-12-18BioMarin Pharmaceutical Inc.$12,483Research paymentCash or cash equivalentVOXZOGO 1.2mg Drug, AchondroplasiaBMN 111-2122025
2025-12-18Intercept Pharmaceuticals, Inc.$7,956Research paymentCash or cash equivalentA Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluatin2025
2025-12-18PFIZER INC.$3,741Research paymentCash or cash equivalentTACTIVEU AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY PK AND ANT2025
2025-12-18E.R. Squibb & Sons, L.L.C.$2,250Research paymentCash or cash equivalentA Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for2025
2025-12-18BioMarin Pharmaceutical Inc.$565Research paymentCash or cash equivalentVOXZOGO 1.2mg Drug, AchondroplasiaBMN 111-2122025
2025-12-18PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-12-18PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-12-18PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-12-18PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-12-17Hoffmann-La Roche Limited$55,054Research paymentCash or cash equivalentPH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD2025
2025-12-17Genentech, Inc.$41,870Research paymentCash or cash equivalentActemra Biological, ImmunologyPHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC2025
2025-12-17E.R. Squibb & Sons, L.L.C.$36,341Research paymentCash or cash equivalentA PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF CC 95266, G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)-TARGE2025
2025-12-17SANOFI US SERVICES INC.$11,721Research paymentCash or cash equivalentA Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination2025
2025-12-17SANOFI US SERVICES INC.$10,053Research paymentCash or cash equivalentTZIELD Biological, Endocrine & Metabolic DiseasesA Real-World Observational Study Characterizing Patients With Type 1 Diabetes Treated with Teplizumab (TEPLI-REAL)2025
2025-12-17AtriCure, Inc.$10,000GrantCash or cash equivalent2025
2025-12-17Intuitive Surgical, Inc.$8,766Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and servicesDAVINCI XI Device, SURGERY2025
2025-12-17Intuitive Surgical, Inc.$6,827Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and servicesDAVINCI XI Device, SURGERY2025
2025-12-17Intuitive Surgical, Inc.$6,583Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and servicesDAVINCI XI Device, SURGERY2025
2025-12-17ABBVIE INC.$6,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentEMBLAVEO Drug, ANTI-INFECTIVE2025
2025-12-17JAZZ PHARMACEUTICALS INC.$4,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentEPIDIOLEX Drug, NEUROLOGY2025
2025-12-17PFIZER INC.$2,177Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYA TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES2025
2025-12-17Abbott Laboratories$998Research paymentCash or cash equivalentMITRACLIP Device, Structural HeartNCT04198870--MitraClip REPAIR MR Study2025
2025-12-16Gilead Sciences, Inc.$100,000GrantCash or cash equivalent2025
2025-12-16Takeda Pharmaceuticals U.S.A., Inc.$6,757Research paymentCash or cash equivalentA PHASE 2B, EXTENSION STUDY TO DETERMINE THE LONG-TERM SAFETY OF VEDOLIZUMAB IV IN PEDIATRIC SUBJECTS WITH ULCERATIVE CO2025
2025-12-16Antares Pharma, Inc.$5,436Research paymentCash or cash equivalentXYOSTED Drug, TESTOSTERONE REPLACEMENT THERAPYOpen-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in M2025
2025-12-16PFIZER INC.$4,105Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTA2025
2025-12-16Olympus America Inc.$4,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentOLYMPUS Device, Ear, Nose, Throat2025
2025-12-16Insmed, Inc.$2,215Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety2025
2025-12-16Insmed, Inc.$2,200Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety2025
2025-12-16PFIZER INC.$1,939Research paymentCash or cash equivalentTACTIVEU AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY PK AND ANT2025
2025-12-16Insmed, Inc.$1,203Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety2025
2025-12-16PTC Therapeutics, Inc.$828Research paymentCash or cash equivalentAN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY2025
2025-12-16Insmed, Inc.$500Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety2025
2025-12-15UCB, Inc.$1,454,762GrantCash or cash equivalent2025
2025-12-15Abbott Laboratories$124,135Research paymentCash or cash equivalentI-STAT TBI CARTRIDGE Device, Point of CareISM2512043A-Traumatic Brain Injury (TBI) test for diagnosis and determination of severity of brain injury in adults and 2025
2025-12-15Merck Sharp & Dohme LLC$106,695Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N2025
2025-12-15Merck Sharp & Dohme LLC$99,574Research paymentCash or cash equivalentSTUDY NAME#Characterize initial post-acute sequelae of Covid-19 cohort using both structured and unstructured electronic2025
2025-12-15Abbott Laboratories$90,421Research paymentCash or cash equivalentI-STAT TBI CARTRIDGE Device, Point of CareISM2512043A-Traumatic Brain Injury (TBI) test for diagnosis and determination of severity of brain injury in adults and 2025
2025-12-15Janssen Research & Development, LLC$41,940Research paymentCash or cash equivalentDARZALEX Drug, OncologyA Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cil2025
2025-12-15Neurocrine BioSciences, Inc.$6,931Research paymentCash or cash equivalentCRENESSITY Drug, NeuropsychiatryGlobal Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal 2025
2025-12-15PFIZER INC.$4,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentNURTEC ODT Drug, PAIN2025
2025-12-15PFIZER INC.$2,450Research paymentCash or cash equivalentXTANDI Drug, ONCOLOGYA RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA2025
2025-12-15Janssen Research & Development, LLC$1,373Research paymentCash or cash equivalentA Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination wi2025
2025-12-15Alkermes, Inc.$70Research paymentIn-kind items and servicesA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-12-12Gilead Sciences, Inc.$125,000GrantCash or cash equivalent2025
2025-12-12ABBVIE INC.$17,979Research paymentCash or cash equivalentVENCLEXTA Drug, ONCOLOGYB19-061 Ph 3 Pediatric Study of venetoclax and chemotherapy2025
2025-12-12AstraZeneca Pharmaceuticals LP$4,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentTEZSPIRE Biological, Respiratory2025
2025-12-12Merck Sharp & Dohme LLC$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentWINREVAIR Biological, CARDIOVASCULAR2025
2025-12-12Stryker Corporation$696Research paymentCash or cash equivalentTORNIER PERFORM REVERSED GLENOID Device, BONE SUBSTITUTESHOULDER ID PRIMARY REVERSED GLENOID OUTCOMES CLINICAL STUDY (SID STUDY; UE-02-2021)2025
2025-12-12Janssen Research & Development, LLC$184Research paymentCash or cash equivalentA Historical Cohort, Multicenter Study to Characterize the Management, Clinical Course, and Outcomes of Pregnancies in W2025
2025-12-11Genentech, Inc.$229,882Research paymentCash or cash equivalent2025
2025-12-11PFIZER INC.$53,304Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITU2025
2025-12-11TAIHO ONCOLOGY, INC.$41,402Research paymentCash or cash equivalentLYTGOBI Drug, OncologyAn Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib Study2025
2025-12-11Regeneron Pharmaceuticals, Inc.$30,029Research paymentCash or cash equivalentA PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS W2025
2025-12-11Intercept Pharmaceuticals, Inc.$27,642Research paymentCash or cash equivalentA Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluatin2025
2025-12-11ABBVIE INC.$27,040Research paymentCash or cash equivalentRINVOQ Biological, IMMUNOLOGYStudy to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric 2025
2025-12-11F. Hoffmann-La Roche AG$18,345Research paymentCash or cash equivalentA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan2025
2025-12-11PFIZER INC.$16,555Research paymentCash or cash equivalentTACTIVEU AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY PK AND ANT2025
2025-12-11Regeneron Pharmaceuticals, Inc.$7,552Research paymentCash or cash equivalentA PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS W2025
2025-12-11Insmed, Inc.$6,375Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety2025
2025-12-11Insmed, Inc.$4,051Research paymentCash or cash equivalentArikayce Drug, RespiratoryA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety2025
2025-12-11Merck Sharp & Dohme LLC$4,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentPIFELTRO Drug, INFECTIOUS DISEASE2025
2025-12-11Regeneron Pharmaceuticals, Inc.$3,972Research paymentCash or cash equivalentA PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS W2025
2025-12-11Regeneron Pharmaceuticals, Inc.$3,938Research paymentCash or cash equivalentA PHASE 1/2A, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY,2025
2025-12-11Stryker Corporation$3,000GrantCash or cash equivalent2025
2025-12-11PFIZER INC.$2,962Research paymentCash or cash equivalentAN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS2025
2025-12-11F. Hoffmann-La Roche AG$2,921Research paymentCash or cash equivalentA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan2025
2025-12-11F. Hoffmann-La Roche AG$1,922Research paymentCash or cash equivalentA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan2025
2025-12-11F. Hoffmann-La Roche AG$1,597Research paymentCash or cash equivalentA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan2025
2025-12-11F. Hoffmann-La Roche AG$1,542Research paymentCash or cash equivalentA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan2025
2025-12-11Regeneron Pharmaceuticals, Inc.$1,426Research paymentCash or cash equivalentA PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS W2025

The latest 200 records of 3,604.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

San Francisco CountySan Francisco city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.

MeasurePlace (city or town)
San Francisco, CA
County
San Francisco County, CA
State
California
Population B01003830,235830,23539,287,377
Population, 2020 census P1873,965873,96539,538,223
Median age B0100240.040.037.9
Under 18 B0100113.7%13.7%22.0%
65 and over B0100117.6%17.6%15.7%
Households B11001363,970363,97013,548,091
Foreign born B0500234.0%34.0%27.0%
Median household income B19013$140,970$140,970$99,122
Median family income B19113$171,141$171,141$113,346
Per capita income B19301$92,289$92,289$49,513
Poverty rate B1700111.2%11.2%12.0%
Unemployment rate B230256.1%6.1%6.6%
Civilian labor force B23025507,262507,26220,068,466
Mean commute (minutes) B0801330.430.428.7
Bachelor's degree or higher B1500360.3%60.3%37.1%
Housing units B25001414,602414,60214,644,735
Owner-occupied B2500338.2%38.2%55.9%
Renters B2500361.8%61.8%44.1%
Median home value B25077$1,394,500$1,394,500$734,700
Median gross rent B25064$2,476$2,476$2,036
White, not Hispanic B0300236.8%36.8%33.8%
Black B030024.7%4.7%5.2%
Hispanic or Latino B0300216.2%16.2%40.2%
Asian B0300234.9%34.9%15.3%
American Indian and Alaska Native B030020.2%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.